- Open Access
Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells
© Sharma et al; licensee BioMed Central Ltd. 2010
- Received: 5 April 2010
- Accepted: 7 July 2010
- Published: 7 July 2010
Trichostatin A (TSA), a potent inhibitor of histone deacetylases exhibits strong anti-tumor and growth inhibitory activities, but its mechanism(s) of action is not completely understood. Osteopontin (OPN) is a secreted glycoprotein which has long been associated with tumor metastasis. Elevated OPN expression in various metastatic cancer cells and the surrounding stromal cells often correlates with enhanced tumor formation and metastasis. To investigate the effects of TSA on OPN transcription, we analyzed a proximal segment of OPN promoter in cervical carcinoma cells.
In this paper, we for the first time report that TSA suppresses PMA-induced OPN gene expression in human cervical carcinoma cells and previously unidentified AP-1 transcription factor is involved in this event. Deletion and mutagenesis analyses of OPN promoter led to the characterization of a proximal sequence (-127 to -70) that contain AP-1 binding site. This was further confirmed by gel shift and chromatin immunoprecipitation (ChIP) assays. Western blot and reverse transcription-PCR analyses revealed that TSA suppresses c-jun recruitment to the OPN promoter by inhibiting c-jun levels while c-fos expression was unaffected. Silencing HDAC1 followed by stimulation with PMA resulted in significant decrease in OPN promoter activity suggesting that HDAC1 but not HDAC3 or HDAC4 was required for AP-1-mediated OPN transcription. TSA reduces the PMA-induced hyperacetylation of histones H3 and H4 and recruitment of RNA pol II and TFIIB, components of preinitiation complex to the OPN promoter. The PMA-induced expression of other AP-1 regulated genes like cyclin D1 and uPA was also altered by TSA. Interestingly, PMA promoted cervical tumor growth in mice xenograft model was significantly suppressed by TSA.
In conclusion, these findings provide new insights into mechanisms underlying anticancer activity of TSA and blocking OPN expression at transcriptional level by TSA may act as novel therapeutic strategy for the management of cervical cancer.
- HeLa Cell
- HDAC Inhibitor
- Electrophoretic Mobility Shift Assay
- SiHa Cell
- Preinitiation Complex
Osteopontin (OPN) is a secreted, noncollagenous, sialic acid-rich, cytokine-like glycosylated phosphoprotein which is a member of S mall I ntegrin B inding L I gand N-linked G lycoprotein (SIBLING) family and plays important role in determining the oncogenic potential of various cancers [1, 2]. OPN expression is increased in a variety of cancers and is reported to correlate with enhanced tumor progression and metastasis [3–5]. OPN plays crucial roles in cancer cell metastasis, granuloma formation, dystrophic calcification and in coronary restenosis [6–11]. The prometastatic effects of OPN like cell adhesion, ECM invasion and cell proliferation are exhibited through interaction with its receptors which regulates various cell signaling pathways ultimately leading to tumor progression . Earlier reports have shown that tumor-derived OPN is soluble and has close similarity with human milk OPN [13, 14]. OPN is also found intracellularly, associated with ezrin and the cytoplasmic domain of CD44. It is important in transducing signals that leads to cytoskeletal rearrangements required during cell migration, fusion and bone resorption [1, 15].
The expression of the genetic information encoded in the DNA is regulated largely by the chromatin structure . Nucleosomes are the repeating units in chromatin which are composed of an octamer core of pairs of histones H2A, H2B, H3 and H4 wrapped with two superhelical turns of DNA around it . Posttranslational covalent modifications of histones like acetylation and methylation of lysines and arginines and phosphorylation of serines have been shown to be important in gene regulation [18, 19]. Acetylation of histones leads to neutralization of the positive charge of lysine residues, resulting in altered chromatin conformation. In this case, promoter regions of genes may be more accessible to transcription factor complexes .
The extent of histone acetylation is determined by the activities of the enzymes histone deacetylases (HDACs) and histone acetyltransferases (HATs) [21–24]. HAT or HDAC activity has been found to be disrupted in many cancers [25–29]. HDAC activity is increased in cancer cells and has been linked to carcinogenesis . Various chemically and structurally diverse agents have been discovered which specifically inhibit HDAC activity. These include first natural product hydroxamate trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), aliphatic compound valproic acid and several other natural and synthetic derivatives [31, 32]. HDAC inhibitors exhibit growth inhibitory and anti-tumor activities like cell cycle arrest, inhibition of cell proliferation and induction of apoptosis in cancer cells both in vitro and tumor-bearing animals [33, 34]. A number of HDAC inhibitors have been shown to be effective in phase I/II clinical trials. However, the mechanisms by which HDAC inhibitors regulate gene expression and show anti-tumor activities are not completely understood and remain to be elucidated .
In the present study, we have examined the effect of HDAC inhibitor, TSA on OPN transcription using human cervical carcinoma as a model. We found that TSA inhibits PMA-induced OPN gene expression. TSA suppressed the PMA-induced c-Jun recruitment to the OPN promoter by inhibiting c-Jun expression both at protein and RNA levels. Our results also identified the previously unrecognized AP-1 binding site in the human OPN promoter which is functionally active. We have also observed that TSA not only suppresses OPN transcription but also inhibits the expression of other AP-1 regulated genes like cyclin D1 and uPA. TSA suppresses the PMA-regulated tumor growth in mice xenograft model. In summary, these results suggest that HDAC inhibitor, TSA suppresses PMA-induced c-Jun expression leading to downregulation of AP-1 regulated genes like OPN, cyclin D1 and uPA. This data revealed that inhibiting OPN transcription by TSA might be an important therapeutic approach for the control of cervical cancer.
Cell culture, antibodies and other reagents
The human cervical carcinoma cell lines, HeLa and SiHa were cultured in Minimum Essential Medium Eagle supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 μg/ml streptomycin and 2 mM glutamine. The cells were maintained in a humidified atmosphere of 5% CO2 and 95% air at 37°C. The anti-OPN antibody was obtained from Chemicon International. The anti-HDAC4, anti-c-Jun, anti-c-Fos, anti-acetyl-H3, anti-acetyl-H4, anti-RNA pol II, anti-TFIIB, anti-cyclin D1, anti-uPA, anti-OPN and anti-actin antibodies were purchased from Santa Cruz Biotechnology. The anti-HDAC1 and anti-HDAC3 antibodies were from Upstate Biotechnology. PMA was purchased from Sigma. Trichostatin A (TSA) was obtained from Cell Signaling Technology. TSA was dissolved in minimum volume of ethanol, further diluted with media and used for in vitro and in vivo studies.
Western blot analysis
HeLa cells were pretreated with TSA (0-1 μM) and then treated with PMA (50 ng/ml). In separate experiments, SiHa cells were treated with TSA (0-2 μM). Cells were lysed in lysis buffer and the lysates containing equal amount of total proteins (30-50 μg) were resolved by SDS-PAGE and blotted onto nitrocellulose membranes. The levels of OPN, c-Jun, c-Fos, cyclin D1 and uPA were analyzed by western blot using their specific antibodies.
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed as described previously . HeLa cells were treated with PMA (50 ng/ml), nuclear extracts (5 μg each) were incubated with γ-32P-labeled double-stranded oligonucleotide containing the AP-1 binding site of OPN promoter in binding buffer (25 mM HEPES (pH 7.9), 0.5 mM EDTA, 0.5 mM DTT, 1% Nonidet P-40, 5% glycerol, and 50 mM NaCl) containing 2 μg of polydeoxyinosinic deoxycytidylic acid (poly dI-dC). The sequence of the probe used was 5' AAC CTC ATG ACA CAA TCT CTC 3'. The DNA-protein complex was resolved on 8% native polyacrylamide gel and analyzed by autoradiography. For supershift assay, the PMA-treated nuclear extracts were incubated with either anti-c-Jun or anti-c-Fos antibody and then EMSA was performed.
RNA isolation and reverse transcription-PCR
RNA isolation and reverse transcription-PCR were performed as mentioned earlier . Briefly, HeLa cells were pretreated with TSA (0-1 μM) followed by treatment with PMA (50 ng/ml). In separate experiments, SiHa cells were treated with TSA (0-2 μM). Total RNA was extracted using Trizol reagent (GIBCO BRL, Grand Island, NY) and reverse transcription-PCR was performed using following sets of primers. OPN (forward 5' AGA CCT GAC ATC CAG TAC CCT G 3', reverse 5' GTG GGT TTC AGC ACT CTG GT 3'), c-jun (forward 5' ATG GAG TCC CAG GAG CGG ATC AA 3', reverse 5' GTT TGC AAC TGC TGC GTT AG 3'), c-fos (forward 5' AAC CGG AGG AGG GAG CTG ACT GAT 3' reverse 5' GGG CCT GGA TGA TGC TGG GAA CA 3'), cyclin D1 (forward 5' CTT CCT CTC CAA AAT GCC AG 3', reverse 5' AGA GAT GGA AGG GGG AAA GA 3'), uPA (forward 5' CAC GCA AGG GGA GAT GAA 3', reverse 5' ACA GCA TTT TGG TGG TGA CTT 3') and actin (forward 5' GGC ATC CTC ACC CTG AAG TA 3', reverse 5' GGG GTG TTG AAG GTC TCA AA 3'). Aliquots of PCR products were analyzed by electrophoresis using 1.2% agarose gel.
Chromatin immunoprecipitation (ChIP) assay
This assay was performed with ChIP assay kit (Upstate Biotechnology, Temecula, CA) according to the manufacturer's instructions. Briefly, cells were cross-linked in 1% formaldehyde solution for 10 min at room temperature. Cells were lysed in 300 μl of SDS lysis buffer and sonicated to generate 200-1000 bp DNA fragments. The cross-linked chromatin in sonicated fractions were immunoprecipitated with anti-p-c-Jun, anti-acetyl H3, anti-acetyl H4, anti-RNA pol II or anti-TFIIB antibody. DNA fragments were analyzed by PCR using specific primers which include AP-1 binding site of OPN promoter (forward 5'-TCT TCC TGG ATG CTG AAT GC-3', reverse 5'-CCA AGC CCT CCC AGA ATT TAA-3').
Construction of expression vectors and site directed mutagenesis
The human OPN promoter fragments (-500/+20, -267/+20, -127/+20) cloned in pGL3 vector were generous gift from Dr. J. H. Chen (Tzu Chi University, Taiwan). Two deletion constructs of the promoter, -70/+20 and -20/+20 were generated by PCR with two 5' primers and a fixed 3' primer. The PCR amplified fragments were digested with Kpn I and Sac I and further cloned into promoter-less luciferase reporter plasmid pGL3-Basic (Promega, Medison, WI). Three mutation constructs namely CM, AM and OM were generated using QuickChange site-directed mutagenesis kit according to the manufacturer's instructions (Stratagene, La Jolla, CA) in which binding sites of CEBPα/AML-1, AP-1 and Oct-1/Oct-2 transcription factors are respectively mutated.
Transfection and luciferase reporter assay
HeLa cells were seeded in 12-well plates and transfected with 2 μg of human OPN promoter deletion and mutation constructs using 4 μl of Lipofectamine 2000 as per the manufacturer's instructions. After 6 h of incubation, the medium was replaced with complete medium. The luciferase activity was measured in cell lysates using dual luciferase reporter assay kit from Promega and normalized to Renilla luciferase activity. Fold-changes in luciferase activity with respect to control were calculated.
Cells were transiently transfected with HDAC1, HDAC3 (siRNA kit from Upstate Biotechnology, Temecula, CA) and HDAC4 (Santa Cruz Biotechnology, Santa Cruz, CA) specific siRNA using Lipofectamine 2000 according to the manufacturer's instructions. These siRNA transfected cells were used for reporter assay and western blot analysis.
In vivo tumorigenicity, histopathology and immunofluorescence
The tumorigenicity and immunofluorescence experiments were performed as described . Briefly, HeLa cells (1 × 106/0.2 ml) were mixed with matrigel (1:1 ratio, BD Biosciences) and injected subcutaneously into the flanks of female NOD/SCID mice (6-8 weeks old). The mice were maintained under specific pathogen-free conditions according to the guidelines of Experimental Animal Facility (EAF) of National Centre for Cell Science. Six mice were used in each group of animals. PMA (10 μg/kg body weight) was injected intratumorally. In some experiments, two doses of TSA (0.5 mg/kg and 4 mg/kg body weight) along with PMA were injected to the site of the tumors. Tumor volume was estimated using the following formula: π/6 [(d1 × d2)3/2], where d1 and d2 are the two perpendicular diameters. Mice were sacrificed after 4 weeks and tumors were excised. The tumors were immediately snap-frozen in liquid nitrogen and the levels of OPN, c-Jun, uPA and cyclin D1 in the tumor lysates were analyzed by western blotting and reverse transcription-PCR. The remaining portions of the tumor samples were formalin fixed and tumor sections were analyzed by immunofluorescence using their specific antibodies.
The results of luciferase reporter and tumorigenicity assay are expressed as mean ± SD and ± SEM respectively. Statistical differences were analyzed by Student's t test. A P value of < 0.05 was considered as significant. All bands were analyzed densitometrically and the fold changes were calculated (Kodak Digital Science).
TSA suppresses PMA-induced OPN transcription in HeLa cells
Deletion and mutagenesis analyses of OPN promoter
The proximal segment of human OPN promoter and its sequence containing various transcription factor binding sites are shown (Additional file 2, Figure S2A and Figure S2B). To characterize the regulatory sequence involved in PMA-induced activation of OPN transcription, a proximal segment (-500 to +20 region) in the human OPN promoter containing C/EBPα/AML-1, AP-1 and Oct-1/Oct-2 transcription factor binding sites was taken into consideration. A region from -500 to +20 of the hOPN promoter sequence and serially deleted promoter sequences (-267/+20, -127/+20, -70/+20 and -20/+20) were cloned into promoter-less luciferase reporter plasmid, pGL3-Basic. The luciferase activity was analyzed in HeLa cells cotransfected with OPN promoter constructs along with Renilla. When luciferase activities of transfected cells were assayed, deletion of the region between -127 and -70 resulted in a dramatic decrease in OPN promoter activity suggesting that AP-1 binding site located in this region might be responsible for OPN transcription in response to PMA (Figure 1C). To further confirm the role of AP-1 binding sequence in PMA-induced OPN expression, mutation constructs were generated, namely CM, AM and OM in which C/EBPα/AML-1, AP-1 and Oct-1/Oct-2 binding sites were respectively mutated. Mutations within the AP-1 binding sequence caused significant reduction in the promoter activity upon PMA treatment (Figure 1D) suggesting the involvement of AP-1 in PMA-induced OPN transcription.
Identification of transcription factor involved in PMA-induced OPN expression
TSA suppresses PMA-induced c-Jun but not c-Fos expression
Determination of acetylation status of histones H3 and H4 in response to PMA and TSA
PMA enhances the recruitment of RNA pol II and TFIIB to OPN promoter, an effect that is reversed by TSA
Previous reports have shown that HDAC inhibitors interfere with the initiation of transcription by blocking the recruitment of components of pre-initiation complex . Therefore, we next examined whether PMA and TSA have any effect on the association of RNA polymerase II and TFIIB with OPN promoter sequence having AP-1 binding site. Employing ChIP assays, we observed that stimulation of HeLa cells with PMA caused induction in the binding of RNA pol II and TFIIB to AP-1 binding region of OPN promoter. The results also revealed that TSA was able to abrogate the PMA-induced RNA pol II and TFIIB association with OPN promoter (Figure 4C and Figure 4D) in a similar manner as observed in the case of histones H3 and H4. These findings suggest that TSA altered the recruitment of components of basal transcription machinery.
Silencing HDAC1 expression leads to decrease in PMA-induced OPN promoter activity
Expression of AP-1 regulated genes in response to PMA and TSA
TSA suppresses cervical tumor growth in response to PMA in NOD/SCID mice xenograft model
HDAC inhibitors have emerged as promising chemotherapeutic agents. Previous studies have demonstrated that these inhibitors exhibit a range of anti-tumor activities including cancer cell cycle arrest, stimulation of differentiation and induction of apoptosis . However, the mechanisms by which HDAC inhibitors show their anticancer activities are not completely understood and remain to be elucidated . Earlier reports have shown that these inhibitors can have effect on gene expression, induce accumulation of acetylated histones and enhance protein degradation, all of which can contribute to the anti-proliferative effects [33, 45, 46]. A possible mechanism by which these inhibitors control cancer cell growth is through downregulation of expression of proteins involved in proliferation and metastasis. One such protein is OPN, elevated levels of which have been linked to enhanced metastatic phenotype. To examine this hypothesis, we investigated the effect of TSA on PMA-induced OPN transcription. In this study, we observed that TSA suppresses OPN transcription in a dose dependent manner both at protein and mRNA levels.
Human OPN promoter deletion and mutagenesis analyses led to the characterization of AP-1 transcription factor being involved in regulation of OPN transcription in response to PMA. Its role in this phenomenon was further confirmed by performing electrophoretic mobility shift assay (EMSA). Supershift assay revealed the presence of c-jun/c-fos heterodimer at the OPN promoter. The in vivo recruitment of c-jun to the OPN promoter was established by chromatin immunoprecipitation assay. TSA was observed to inhibit this recruitment. Moreover, Sakata et al have demonstrated that TSA activates the OPN gene promoter through AP-1 site in mouse undifferentiated mesenchymal cell line . We addressed the question how the recruitment of c-jun to the OPN promoter was affected by TSA in cervical cancer cells. One possible mechanism could be by changing the c-jun expression. To validate this hypothesis, c-jun expression was analyzed by western blot as well as by RT-PCR. Interestingly, the data revealed that TSA inhibited c-jun transcription affecting both protein and mRNA levels which leads to the reduction in c-jun binding to the OPN promoter. To our surprise, c-fos levels were unchanged by PMA and TSA treatment. We also investigated the acetylation status of histones H3 and H4 associated with the AP-1 binding sequence of OPN promoter. Employing ChIP assays, we observed that TSA inhibits the hyperacetylation of histones H3 and H4 which is induced by PMA. This could be one of the mechanisms by which OPN expression is suppressed by TSA since acetylation status of the histones is directly correlated with gene expression. This report also showed that TSA can block the recruitment of components of the preinitiation complex viz RNA polymerase II and TFIIB to the OPN promoter. These findings were consistent with previous evidence that HDAC activity is required to recruit the preinitiation complex to selected genes that are activated by the transcription factors Stat 1, Stat 2 and Stat 5 [48, 49].
Histone deacetylases have been divided into different classes. HDAC1, but not HDAC3 and HDAC4 seemed to be required for OPN transcription in response to PMA as determined by siRNA transfection experiments. OPN promoter activity was significantly reduced upon silencing HDAC1 suggesting its importance in the regulation of OPN expression by PMA. Since it was observed that TSA inhibits the PMA-induced OPN transcription by altering the expression of c-jun, we sought to determine whether TSA has any effect in regulation of expression of other c-jun specific target genes. Indeed, the expression of two well-known AP-1 regulated genes, cyclin D1 and uPA, was suppressed by TSA suggesting the strong anti-tumor activities of TSA. HDAC inhibitors have more profound effect on the growth of tumor cells than the normal cells . Tumor cells have increased levels of OPN, c-jun, cyclin D1 and uPA. Our results revealed that the expression levels of OPN, c-Jun and c-Fos are higher in SiHa as compared to HeLa cells. This might be due to the fact that SiHa cells are more invasive than HeLa cells. All these oncogenic molecules have been shown to play important role in regulation of tumor growth, proliferation and metastasis. Therefore, it may be hypothesized that the growth inhibitory activities of TSA might be due to the down regulation of OPN, c-jun, cyclin D1 and uPA in both HeLa and SiHa cells.
In summary, this is the first time we report that TSA suppresses the PMA-induced transcription of OPN in cervical cancer model. Thus, this evidence suggested that the transcription factor, AP-1 has the binding ability to the OPN regulatory region that ultimately regulates the expression of OPN gene, which leads to tumor progression in cervical cancer (Figure 7D). Thus, inhibiting OPN expression at the transcriptional level by TSA might provide a novel strategy for the prevention of cervical cancer.
This study has investigated the effects of HDAC inhibitor, TSA on OPN transcription and characterized the transcription factor binding site in the OPN promoter that plays an important role in this phenomenon. The data revealed that TSA suppresses the PMA-induced OPN gene expression in a dose dependent manner and induction of OPN transcription by PMA is mediated via AP-1 transcription factor that forms a heterodimer of c-jun and c-fos at the OPN promoter. The results also indicated that TSA suppressed the PMA-induced c-Jun recruitment to the OPN promoter by inhibiting c-Jun expression. The PMA-induced hyperacetylation of histones H3 and H4 associated with OPN promoter is also inhibited by TSA. Moreover, PMA promoted cervical tumor growth was significantly reduced by TSA in mice xenograft model. All these results highlight the mechanism of action of TSA and suggest that the growth inhibitory and anti-tumor activities of TSA might be exhibited, in part, by downregulation of OPN expression. Furthermore, this study represents OPN as possible candidate for anticancer therapies and blocking OPN expression at transcriptional level by TSA might provide a new strategy for management of cervical cancer.
This work was supported in part by Council of Scientific and Industrial Research, Government of India (to P. Sharma) and University Grant Commission, Government of India (to S. Kumar).
- Sodek J, Ganss B, McKee MD: Osteopontin. Crit Rev Oral Biol Med. 2000, 11: 279-303. 10.1177/10454411000110030101View ArticlePubMedGoogle Scholar
- Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006, 6: 819-830. 10.2174/156652406779010803View ArticlePubMedGoogle Scholar
- Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF: A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983, 302: 714-715. 10.1038/302714a0View ArticlePubMedGoogle Scholar
- Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994, 145: 610-623.PubMed CentralPubMedGoogle Scholar
- Craig AM, Bowden GT, Chambers AF, Spearman MA, Greenberg AH, Wright JA, McLeod M, Denhardt DT: Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer. 1990, 46: 133-137. 10.1002/ijc.2910460124View ArticlePubMedGoogle Scholar
- Giachelli CM, Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000, 19: 615-622. 10.1016/S0945-053X(00)00108-6View ArticlePubMedGoogle Scholar
- Weber GF: The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta. 2001, 1552: 61-85.View ArticlePubMedGoogle Scholar
- Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS: Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001, 107: 1055-1061. 10.1172/JCI12980PubMed CentralView ArticlePubMedGoogle Scholar
- Tuck AB, Chambers AF: The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia. 2001, 6: 419-429. 10.1023/A:1014734930781View ArticlePubMedGoogle Scholar
- Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001, 1: 621-632. 10.2174/1566524013363339View ArticlePubMedGoogle Scholar
- Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K, Mukherjee AB: Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA. 1997, 94: 9308-9313. 10.1073/pnas.94.17.9308PubMed CentralView ArticlePubMedGoogle Scholar
- Wai PY, Kuo PC: The role of OPN in tumor metastasis. J Surg Res. 2004, 121: 228-241. 10.1016/j.jss.2004.03.028View ArticlePubMedGoogle Scholar
- Rittling SR, Chen Y, Feng F, Wu Y: Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem. 2002, 277: 9175-9182. 10.1074/jbc.M109028200View ArticlePubMedGoogle Scholar
- Senger DR, Perruzzi CA, Papadopoulos A, Tenen DG: Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta. 1989, 996: 43-48.View ArticlePubMedGoogle Scholar
- Suzuki K, Zhu B, Rittling SR, Denhardt DT, Goldberg HA, McCulloch CA, Sodek J: Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res. 2002, 17: 1486-1497. 10.1359/jbmr.2002.17.8.1486View ArticlePubMedGoogle Scholar
- Felsenfeld G, Groudine M: Controlling the double helix. Nature. 2003, 421: 448-453. 10.1038/nature01411View ArticlePubMedGoogle Scholar
- Spotswood HT, Turner BM: An increasingly complex code. J Clin Invest. 2002, 110: 577-582.PubMed CentralView ArticlePubMedGoogle Scholar
- Jenuwein T, Allis CD: Translating the histone code. Science. 2001, 293: 1074-1080. 10.1126/science.1063127View ArticlePubMedGoogle Scholar
- Zhang Y, Reinberg D: Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001, 15: 2343-2360. 10.1101/gad.927301View ArticlePubMedGoogle Scholar
- Allfrey VG: Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc Can Cancer Conf. 1966, 6: 313-335.PubMedGoogle Scholar
- Johnson CA, Turner BM: Histone deacetylases: complex transducers of nuclear signals. Semin Cell Dev Biol. 1999, 10: 179-188. 10.1006/scdb.1999.0299View ArticlePubMedGoogle Scholar
- Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D: Functional significance of histone deacetylase diversity. Curr Opin Genet Dev. 2001, 11: 162-166. 10.1016/S0959-437X(00)00174-XView ArticlePubMedGoogle Scholar
- Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1: 194-202. 10.1038/35106079View ArticlePubMedGoogle Scholar
- Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu Rev Biochem. 2001, 70: 81-120. 10.1146/annurev.biochem.70.1.81View ArticlePubMedGoogle Scholar
- Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001, 92: 1300-1304.View ArticlePubMedGoogle Scholar
- Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, Delhanty JD, Ponder BA, Kouzarides T, Caldas C: Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000, 24: 300-303. 10.1038/73536View ArticlePubMedGoogle Scholar
- Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-428. 10.1038/nrg962View ArticlePubMedGoogle Scholar
- Lehrmann H, Pritchard LL, Harel-Bellan A: Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res. 2002, 86: 41-65. full_textView ArticlePubMedGoogle Scholar
- Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM: ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA. 1998, 95: 10860-10865. 10.1073/pnas.95.18.10860PubMed CentralView ArticlePubMedGoogle Scholar
- Kawai H, Li H, Avraham S, Jiang S, Avraham HK: Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer. 2003, 107: 353-358. 10.1002/ijc.11403View ArticlePubMedGoogle Scholar
- Yoshida M, Kijima M, Akita M, Beppu T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990, 265: 17174-17179.PubMedGoogle Scholar
- Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA. 2002, 99: 11700-11705. 10.1073/pnas.182372299PubMed CentralView ArticlePubMedGoogle Scholar
- Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA: Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA. 1996, 93: 5705-5708. 10.1073/pnas.93.12.5705PubMed CentralView ArticlePubMedGoogle Scholar
- Marks PA, Richon VM, Breslow R, Rifkind RA: Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001, 13: 477-483. 10.1097/00001622-200111000-00010View ArticlePubMedGoogle Scholar
- Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell. 2003, 4: 13-18. 10.1016/S1535-6108(03)00165-XView ArticlePubMedGoogle Scholar
- Philip S, Kundu GC: Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2003, 278: 14487-14497. 10.1074/jbc.M207309200View ArticlePubMedGoogle Scholar
- Liu YN, Kang BB, Chen JH: Transcriptional regulation of human osteopontin promoter by C/EBP and AML-1 in metastatic cancer cells. Oncogene. 2004, 23: 278-288. 10.1038/sj.onc.1207022View ArticlePubMedGoogle Scholar
- Chakraborty G, Jain S, Kundu GC: Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68: 152-161. 10.1158/0008-5472.CAN-07-2126View ArticlePubMedGoogle Scholar
- Marks PA, Rifkind RA, Richon VM, Breslow R: Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res. 2001, 7: 759-760.PubMedGoogle Scholar
- Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000, 97: 10014-10019. 10.1073/pnas.180316197PubMed CentralView ArticlePubMedGoogle Scholar
- Munster PN, Troso-Sandoval T, Rosen N, Rifkind RA, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001, 61: 8492-8497.PubMedGoogle Scholar
- Fass DM, Butler JE, Goodman RH: Deacetylase activity is required for cAMP activation of a subset of CREB target genes. J Biol Chem. 2003, 278: 43014-43019. 10.1074/jbc.M305905200View ArticlePubMedGoogle Scholar
- Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M: In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002, 24: 6820-6831. 10.1093/emboj/cdf682.View ArticleGoogle Scholar
- Gabrielli BG, Johnstone RW, Saunders NA: Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets. 2002, 2: 337-353. 10.2174/1568009023333818View ArticlePubMedGoogle Scholar
- Kouzarides : Acetylation: A regulatory modification to rival phosphorylation?. EMBO J. 2000, 19: 1176-1179. 10.1093/emboj/19.6.1176PubMed CentralView ArticlePubMedGoogle Scholar
- Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS: Modulation of p53, ErbB1, ErbB2 and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002, 94: 504-513.View ArticlePubMedGoogle Scholar
- Sakata R, Minami S, Sowa Y, Yoshida M, Tamaki T: Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem Biophys Res Commun. 2004, 315: 959-963. 10.1016/j.bbrc.2004.01.152View ArticlePubMedGoogle Scholar
- Sakamoto S, Potla R, Larner AC: Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem. 2004, 279: 40362-40367. 10.1074/jbc.M406400200View ArticlePubMedGoogle Scholar
- Rascle A, Johnston JA, Amati B: Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol. 2003, 23: 4162-4173. 10.1128/MCB.23.12.4162-4173.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG: Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer. 1999, 80: 1252-1258. 10.1038/sj.bjc.6690493PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.